Abstract:PURPOSE:This study aimed to evaluate the difference of mass in dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) characteristics between low-risk and non-low-risk breast cancers and to explore the possible pathological basis.MATERIALS AND METHODS:Approval from the institutional review board and informed consent were acquired for this study. The MR images of 104 patients with pathologically proven breast cancer (104 lesions) were prospectively analyzed. All of included patients were Chinese woman. The DCE-MRI morphologic findings, apparent diffusion coefficient (ADC) values, quantitative DCE-MRI parameters, and pathological biomarkers between the two subtypes of breast cancer were compared. The quantitative DCE-MRI parameters and ADC values were added to the morphologic features in multivariate models to evaluate diagnostic performance in predicting low-risk breast cancer. The values were further subjected to the receiver operating characteristic (ROC) curve analysis.RESULTS:Low-risk tumors showed significantly lower Ktrans and Kepvalues (t = 2.065, P = 0.043 and t = 3.548, P = 0.001, respectively) and higher ADC value (t = 4.713, P = 0.000) than non-low-risk breast cancers. Our results revealed no significant differences in clinic data and conventional imaging findings between the two breast cancer subtypes. Adding the quantitative DCE-MRI parameters and ADC values to conventional MRI improved the diagnostic performance of MRI: The area under the ROC improved from 0.63 to 0.91. Low-risk breast cancers showed significantly lower matrix metalloproteinase (MMP)-2 expression (P = 0.000), lower MMP-9 expression (P = 0.001), and lower microvessel density (MVD) values (P = 0.008) compared with non-low-risk breast cancers. Ktrans and Kep values were positively correlated with pathological biomarkers. The ADC value showed a significant inverse correlation with pathological biomarkers.CONCLUSIONS:The prediction parameter using Ktrans, Kep, and ADC obtained on DCE-MRI and diffusion-weighted imaging could facilitate the identification of low-risk breast cancers. Decreased biological factors, including MVD, vascular endothelial growth factor, MMP-2, and MMP-9, may explain the possible pathological basis.

Quantitative detection of CC chemokine ligand 5 and matrix metalloproteinase-9 by QDs-based molecular prediction of breast cancer by

Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer.

Biomarker Discovery To Improve Prediction Of Breast Cancer Survival: Using Gene Expression Profiling, Meta-Analysis, And Tissue Validation

The prognostic value of quantitative analysis of CCL5 and collagen IV in luminal B (HER2-) subtype breast cancer by quantum-dot-based molecular imaging.

Quantum dot-based in situ simultaneous molecular imaging and quantitative analysis of EGFR and collagen IV and identification of their prognostic value in triple-negative breast cancer

The Quantitative Detection of Total HER2 Load by Quantum Dots and the Identification of a New Subtype of Breast Cancer with Different 5-Year Prognosis.

Quantitative molecular diagnosis of axillary drainage fluid for prediction of locoregional failure in patients with one to three positive axillary nodes after mastectomy without adjuvant radiotherapy.

Detection of serum VEGF and MMP-9 levels by Luminex multiplexed assays in patients with breast infiltrative ductal carcinoma

Quantum Dots-Based Quantitative And In Situ Multiple Imaging On Ki67 And Cytokeratin To Improve Ki67 Assessment In Breast Cancer

CCDC69 is a prognostic marker of breast cancer and correlates with tumor immune cell infiltration

Bioinformatics, Molecular Docking and Experiments In Vitro Analyze the Prognostic Value of CXC Chemokines in Breast Cancer

Quantum dots-based molecular classification of breast cancer by quantitative spectroanalysis of hormone receptors and HER2.

Quantifying spatial CXCL9 distribution with image analysis predicts improved prognosis of triple-negative breast cancer

Biomarker Quantification by Multiplexed Quantum Dot Technology for Predicting Lymph Node Metastasis and Prognosis in Head and Neck Cancer

Prediction of Breast Cancer Prognosis by Midkine,Survivin and MMP2 Detection

Prediction of Low-Risk Breast Cancer Using Quantitative DCE-MRI and Its Pathological Basis

Comprehensive analysis of the prognostic value and immune function of chemokine-CXC receptor family members in breast cancer.

Diagnostic and prognostic value of the cancer-testis antigen lactate dehydrogenase C4 in breast cancer

A Panel Containing PD-1, IL-2Rα, IL-10, and CA15-3 As a Biomarker to Discriminate Breast Cancer from Benign Breast Disease.

Prognostic significance of the matrix metalloproteinase-11 expression in tumor cells in invasive ductal carcinoma of the breast

CXCL9 Is a Potential Biomarker of Immune Infiltration Associated With Favorable Prognosis in ER-Negative Breast Cancer